Indeed, in preclinical models, constitutive overexpression of IGFBP3 was associated with reduced islet mass and dysglycemia21, and our results demonstrate that short-term IGFBP3 exposure in vivo alters glycometabolic control in naive mice, although diabetes itself may alter IGFBP3 distribution and clearance30, thus indicating that elevated IGFBP3 levels are involved in beta-cell loss/dysfunction. This evidence concerns the gene IGFBP3 and diabetes mellitus.